Mecasermin - Chiron/SkyePharma

Drug Profile

Mecasermin - Chiron/SkyePharma

Alternative Names: D 0601; DepoIGF-1; IGF-1 - Chiron/SkyePharma; IGF-1 - DepoFoam; Insulin-like growth factor-1 - Chiron/SkyePharma; Insulin-like growth factor-1 - DepoFoam; rhIGF-1 - Chiron/SkyePharma; Somatomedin-1 - Chiron/SkyePharma; Somatomedin-1 - DepoFoam

Latest Information Update: 10 Aug 2000

Price : $50

At a glance

  • Originator Chiron Corporation
  • Developer Chiron Corporation; SkyePharma Inc
  • Class Antihyperglycaemics; Growth factors; Peptides
  • Mechanism of Action Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Osteoarthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Aug 2000 Discontinued-II for Osteoarthritis in USA (Intra-articular)
  • 14 Feb 2000 DepoTech is now called SkyePharma Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top